Natera Receives Unique Z-Code for Its Kidney Transplant Rejection Monitoring Test

Represents a Key Milestone Towards Achieving Medicare Reimbursement SAN CARLOS, Calif., Nov. 28, 2018 -- (Healthcare Sales & Marketing Network) -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the assignment of ... Diagnostics, Reimbursement Natera, cell-free DNA, Kidney Transplant, Transplant Rejection
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news